Currently out of the existing stock ratings of Matthew L Kaplan, 1734 are a BUY (83.33%), 347 are a HOLD (16.67%).

Matthew L Kaplan

Work Performance Price Targets & Ratings Chart

Analyst Matthew L Kaplan, currently employed at LADENBURG, carries an average stock price target met ratio of 50.83% that have a potential upside of 42.3% achieved within 510 days.

Matthew L Kaplan’s has documented 63 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on UTHR, United Therapeutics at 25-Feb-2022.

Wall Street Analyst Matthew L Kaplan

Analyst best performing recommendations are on TGTX (TG THERAPEUTICS).
The best stock recommendation documented was for TGTX (TG THERAPEUTICS) at 5/12/2020. The price target of $44 was fulfilled within 217 days with a profit of $24.06 (120.66%) receiving and performance score of 5.56.

Average potential price target upside

of $50.01 (63.88%) on RETA (REATA PHARMACEUTICALS).
of $22.74 (27.7%) on UTHR (UNITED THERAPEUTICS).
of $13.21 (81.25%) on TGTX (TG THERAPEUTICS).

ARDX Ardelyx AXSM Axsome Therapeutics LPCN Lipocine MLND Millendo Therapeutics RETA Reata Pharmaceuticals TGTX TG Therapeutics UTHR United Therapeutics ALNA Allena Pharmaceuticals BDSI BioDelivery Sciences International RPHM Reneo Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ed Arce (HC WAINWRIGHT)